对干扰素基因激动剂激活剂的更新专利审查 (2021年至今)
Guo-Feng Xin1,2, Nan-Nan Chen1,2, Lin-Lin Li1,2
1State Key Laboratory of Natural Medicines, and Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, China.
Expert opinion on therapeutic patents
|June 7, 2024
概括
干扰素基因刺激剂 (STING) 激素激活天生的免疫力,促进抗瘤反应. 本综述涵盖了从2021年1月到2023年10月的癌症治疗的STING激进分子结构和药理学.
科学领域:
- 免疫学 免疫学 免疫学
- 药用化学 医学化学
- 在瘤学瘤学.
背景情况:
- 干扰素基因刺激器 (STING) 是一个关键的先天免疫传感器.
- 刺激激活导致细胞因子和I型干扰素的产生.
- 这一途径可以增强适应性免疫力,包括对瘤的CD8+T细胞反应.
研究的目的:
- 为提供作为抗癌剂的STING激动剂的药物化学概述.
- 审查CDN类和非核酸STING激动剂的结构和药理学数据.
- 涵盖2021年1月至2023年10月的文献.
主要方法:
- 科学出版物和专利数据库的文献评论.
- 分析来自蛋白质数据库的结构数据.
- 来自各种来源的药理学数据的汇编.
主要成果:
- 识别结构多样化的STING激动剂.
- 编制各种STING激动剂的药理学概况.
- 在癌症治疗中STING激动剂发展的概述.
结论:
- 刺痛激动剂代表了癌症免疫治疗的有希望的策略.
- 已经确定了STING激动剂的多种化学结构.
- 进一步的研究和开发有潜力克服STING激动剂治疗中的挑战.
关键词:
刺痛的激动剂是刺痛的激动剂干扰素基因 (STING) 的刺激器cGAS-STING 的使用情况.癌症治疗疗法 癌症治疗免疫疗法 免疫疗法patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent
相关概念视频
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:25Inhibitors Of Virion Release
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
01:19Inhibitors of Virion Maturation and Assembly
As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...